Robert Cerwinski: The Potential for an Executive Order on Drug Pricing

Robert Cerwinski, JD, Partner at Goodwin, discusses the potential for an upcoming executive order on drug pricing. 
September 04, 2017


Transcript:

Can we expect to see an executive order on drug pricing in the coming months? 

You know, I think the executive branch is a little bit at odds with itself. We are not really sure from one day to the next what the priorities are going to be, and with all of the debate right now over Obamacare, I really cannot say that we can predict that with any degree of certainty. I think all that we can predict, when it comes to healthcare, is that the executive branch is going to continue to surprise us.

x-button

Click here to view Biosimilars CME Activities

Click here to view Biosimilars PTCE Activities

Health economics experts. Managed care professionals. Key clinical specialists. This is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical biotechnology meet: The Center for Biosimilars is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We’ll discuss the current landscape for advanced health care management—reviewing emerging treatment paradigms, approaches, and considerations—all by authoritative industry voices.

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright © 2006-2019 Intellisphere, LLC. All Rights Reserved.